ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]
ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]